Andere Sprachen Immatics N.V.

Aktien

A2P72S

NL0015285941

IMTX

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 15.01.2026			% 5 Tage	Veränd. 1. Jan.
9,920 ^USD	+0,92 %		+6,44 %	-5,52 %

06.01.	Biotech-Sektor steht laut BofA vor Wachstumsschub durch Studiendaten und Pharma-Deals	MT
06.01.	IMMATICS N.V. : Bewertung von BofA Securities kaufen	ZM

Andere Sprachen

06.01.	Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says
11.12.	Immatics N : 251211 IMTX IMA203CD8 ESMO-IO FINAL
11.12.	Immatics N.V. Provides Updated Dose Escalation Data from its Phase 1a Clinical Trial Evaluating its Second-Generation PRame Cell Therapy, IMA203CD8
11.12.	Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
05.12.	Immatics announces $125 million underwritten offering
05.12.	Immatics Plans $125 Million Stock Offering
05.12.	Immatics Announces $125 Million Underwritten Offering
17.11.	Sector Update: Health Care Stocks Mixed Pre-Bell Monday
17.11.	Immatics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
17.11.	Immatics Q3 Net Loss Widens, Revenue Drops
17.11.	Earnings Flash (IMTX) Immatics Posts Q3 Net Loss 0.42 Euros a Share, vs. FactSet Est of 0.37 Euros Loss
17.11.	Immatics: Q3 Earnings Snapshot
17.11.	Immatics Announces Third Quarter 2025 Financial Results and Business Update
12.11.	Immatics Says Two Product Candidates Show Favorable Tolerability in Patients With Solid Tumors
12.11.	Immatics N : 251010 TCER Data Release Nov 2025
12.11.	Immatics N.V. Provides Updated Data on the Phase 1a Dose Escalation of IMA402 MageA4/8 Bispecific
12.11.	Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
27.10.25	Immatics N : 251027 SMR TiP Poster SUPRAME Anzu-cel Phase 3 Trial in Advanced Cutaneous Melanoma
27.10.25	Immatics N.V. Appoints Amie Krause as Chief People Officer, Effective October 27, 2025
27.10.25	Immatics Appoints Amie Krause as Chief People Officer
20.10.25	Immatics N : 251020 ESMO Anzu-cel Uveal Melanoma Presentation FINAL
20.10.25	Immatics Says Anzu-cel Shows 'Strong' Anti-Tumor Activity in Uveal Melanoma Trial; Shares Rise
20.10.25	Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
20.10.25	Immatics N.V. Provides Updated Data from 16 Patients with Metastatic Uveal Melanoma in the Ongoing Phase 1b Clinical Trial Evaluating anzu-cel PRame Cell Therapy
01.10.25	Immatics Names Venkat Ramanan CFO

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Andere Sprachen Immatics N.V.

Aktien

A2P72S

NL0015285941

IMTX

Biotechnologie

Andere Sprachen

Filter